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Summary 
Aim  
We set out to determine the potential contribution of community pharmacists to improve the 
transfer of care of patients from secondary to primary care settings.  
Method  
We systematically reviewed the literature on interventions that involved community pharmacy at 
the post discharge stage. We considered all relevant studies, including both randomised and non-
randomised controlled trials, irrespective of patient population. Our primary outcome was any 
impact on patient and medication outcomes, while the secondary outcome was to identify 
intervention characteristics that influenced all reported outcomes. 
Results  
We retrieved 14 studies that met our inclusion criteria. Those studies reporting outcomes relating to 
the identification and rectification of medication errors were significantly improved with community 
pharmacy involvement. Other patient outcomes such as medication adherence and clinical control 
were not unanimously positively or negatively influenced via the inclusion of community pharmacy 
in a transfer of care post discharge intervention. Some inconsistencies in implementation and 
process evaluation of interventions were found across the reviewed studies; this limited the 
accuracy with which true impact could be considered. 
Conclusions  
The evidence of community pharmacy involvement in interventions aimed at improving the 
continuity of care (other than those relating to medication errors) is not consistent. Further studies 
are required which include process evaluations to fully describe the context of the intervention so as 
to better determine any influencing factors. Also applying more stringent controls and closer 
adherence to protocols in both intervention and control groups would allow clearer correlations to 
be made between the intervention and the outcomes. 
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Introduction 
The transition of patients from primary to secondary care settings (and vice versa) is historically 
acknowledged as risky. Twenty percent of patients have been reported to experience adverse events 
within three weeks of discharge, 60% of which could have been ameliorated or avoided [1]. Patients 
are exposed to errors, which can have a detrimental effect on their health, recovery and overall 
satisfaction with the healthcare system [2,3]. 
Patients are often departing from a confusing and hectic discharge environment, supplied with 
messages about medicines management, follow-up appointments and other post-discharge 
information. The process is vulnerable to misunderstanding and miscommunication, often leaving 
the patient, carers and families ill-prepared to appropriately manage their care during the transition 
home [3,4]. Only 10% of elderly patients will be discharged on the same medication that they were 
admitted to hospital on [5]. Sixty percent of patients will have three or more medicines changed 
during their hospital stay [6]; 28-40% of medications are stopped within hospital, and 45% of 
medicines prescribed at discharge are new [7]. 
Pharmacists can potentially play a key role in patient care, especially at these transitions [8]. Indeed, 
the Royal Pharmaceutical Society of Great Britain (RPSGB) in 1992 advocated that hospital 
pharmacists should produce documentation for patients on discharge so as to assist with 
communication when they leave one healthcare setting and enter another [9]. The restructuring of 
the NHS in England, with the introduction of Clinical Commissioning Groups (CCGs) and their support 
and encouragement for new health care providers, has re-emphasised the important role the 
pharmacist can play in these transitions [10]. The working party responsible for the RPSGB report 
recommends fostering links within the community between pharmacists, clinicians, nurse, etc., so as 
to ensure patient needs are met when they move between healthcare settings [11]. Community 
pharmacists can offer accessibility, expertise in therapeutics, face-to-face contact and skills in drug 
problems and adherence [10,12]. A recent report from the Royal Pharmaceutical Society (RPS) 
(previously RPSGB), ‘Keeping patients safe when they transfer between care providers – getting the 
medicines right’ (June 2012), provides guidance on the medicine information that should accompany 
a patient from one care setting another [13]. Early adopter sites of this guidance piloted and trailed 
various interventions and services, many of which involved a role for community pharmacy. The 
adopting hospitals recognised the contribution of community pharmacies and begun referring 
patients for a Medicines Use Review (MUR) or New Medicines Service (NMS) consultation post-
discharge [14]. Urban et al. [15] summarise that poor communication to community pharmacists at 
discharge can cause unintended medication discrepancies and hinder continuity. They further 
promote the provision of consistent and timely communication to community pharmacy post 
discharge to ensure seamless transition and reduction in adverse issues.  
Although much literature has been published on the positive input of hospital pharmacists on 
admission and during discharge [4, 16, 17], less is known about their community counterparts and 
the effects of their interventions on patient outcomes. The RPS report [13] which recommended the 
improvement of communication during patient transfer and the increasing recognition and evidence 
of the clinical skills of community pharmacists, should lead to an increase in more clinical services 
being provided and commissioned within the community. 
Some studies have restricted the interventions of interest to medicines reconciliation or medication 
review, and have limited the population to, for example, those suffering from heart failure [18]. 
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Others have investigated the potential of post-discharge (PD) community pharmacy interventions to 
improve continuity of care [2, 8, 19-22]. 
We therefore aim to systematically evaluate and quantify the effects of community pharmacy 
interventions on all potential outcomes of patients of all demographics and conditions discharged 
from hospital and considered to be at a point of transition. 
Methods 
Searching  
The Cochrane Collaboration glossary of terms and the University of York guidelines for the conduct 
of systematic reviews and search strategies were consulted to frame the search. The included key 
points of research reporting, as specific in the Consolidated Standards of Reporting Trials (CONSORT) 
guidelines [23] for the publication of research describing RCTs, was utilised to assess the clarity of 
reporting in the included studies. Our search strategy identified research on interventions made or 
contributed by community pharmacies after hospital discharge. The following electronic databases 
were searched to identify evidence: MEDLINE, EMBASE, CINAHL, NHS EED, Cochrane Controlled 
Trials Register, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of 
Effects (DARE) and Web of Science. Trial registers and websites of funding organisations were 
searched for ongoing studies. On-line search of The Pharmaceutical Journal as well as hand searches 
of relevant conference abstracts (such as the RPS conferences) were conducted. Hand searches 
through reference lists of key articles was also undertaken and relevant information on unpublished 
and in-progress research from key-experts in the field was requested and included. 
Key words and synonyms used in the electronic search to frame the setting or aim of healthcare 
provision included: continuity of care, continuous care, continuum of care, seamless care, barriers to 
care, and ongoing care. Word derivatives for interventionists included: pharmacist, pharmacy, 
pharmacies, community pharmacy, pharmacy services and pharmacy practice. The search filters 
used were: randomised controlled trials; controlled clinical trials, random allocation, single-blind 
method, clinical trials, crossover trials and placebos.  
Study selection 
All titles retrieved via literature search were reviewed by one of the authors (HN) for relevance. Two 
of the authors (HN and ZN) then independently assessed the abstracts of these papers against the 
inclusion criteria. The studies were delineated by their reported population/patient, intervention, 
control, and outcomes and included: (i) the population of patients which were identified as post-
discharge; (ii) intervention involved a community pharmacist or member of the community 
pharmacy team; (iii) intervention focussed on continuity of care, transfer of care or follow-up care; 
(iv) intervention occurred post-discharge from a hospital setting; (v) controlled trials that were 
randomised or non-randomised; (v) all reported outcomes were of interest. Papers were not 
excluded on the basis of language, country of origin or publication date. Full papers from those 
abstracts that were considered relevant were requested and assessed independently by the two 
authors for their suitability for inclusion and differences resolved by discussion with reference to a 
third reviewer (AT) if necessary. 
Validity assessment 
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Validity assessment was guided by criteria recommended by Cochrane for assessing methodological 
quality [24]. Blinding of the assessors was not considered specifically relevant to the end-points of 
the studies; we therefore critiqued studies for potential influence of bias or confounding factors 
impacting on reported outcomes. We compared baseline characteristics of groups, and reported 
whether the studies described the clear and transparent flow of patients and why, if any, losses or 
drop-outs occurred. We also clearly defined primary and secondary outcomes, and provided a 
sample size calculation. We reported whether >80% of patients were retained in the trial, as well as 
any training that the pharmacists received or resources they required for the intervention. Two 
authors (HN and ZN) independently carried out this analysis and any discrepancies were resolved 
through discussion with the third author (AT). The appraisal will be used for descriptive purposes 
and will also highlight variations between studies. 
Data abstraction 
Data were extracted on a piloted data extraction form adapted from an established Cochrane 
version. Two authors (HN and ZN) extracted data independently and checked for agreement or 
discrepancies. The third author (AT) was consulted for additional review where appropriate. Data 
included type of participants, intervention details, outcomes and trial quality characteristics. 
Study characteristics 
Classification of interventions: Interventions had to be delivered by a community pharmacist or 
member of the community pharmacy team. Singular or multiple interventions made by other 
healthcare professionals only (excluding community pharmacies post-discharge) were excluded. All 
forms of intervention made PD from a hospital setting were considered. All populations of patients 
were considered irrespective of their age, clinical condition or diagnosis, etc. All subsequent 
outcomes from interventions were considered including ‘soft’, e.g., patient satisfaction, medication 
adherence, and ‘hard’, e.g., clinical test results, mortality. Studies were categorised by: type of 
patient population; intervention components; funding/resources required for intervention; 
intervention preference compared to control. 
Outcomes: Due to heterogeneity in outcomes measured, all outcomes have been considered and 
reported. Outcome data were extracted at the study’s pre-specified last follow-up point. Formal 
pooling for meta-analysis was not possible due to the diversity of outcomes and scales employed, 
but informal pooling highlights were studies showed a significant positive, non-significant positive, 
negative or no effect. 
Results 
Search results and study characteristics 
A total of 1,528 titles were identified from our literature search, which yielded 144 potentially 
relevant studies. Further assessment of the abstracts of these studies and hand searches led to a 
total of 14 controlled trials identified that fit the inclusion criteria for the review. Figure 1 describes 
the steps involved in the search and selection process.   
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Figure 1. Flowchart describing study selection and excluded studies 
Two of the studies which focussed on “warfarinised” patients were controlled but with no 
randomisation [25, 26], one further study was non-randomised [27], and another was an economic 
evaluation of a particular randomised control trial [28] with the trial itself also included [29]. Four of 
the studies were carried out in Australia [25, 26, 30, 31], five in the UK [19, 28, 29, 32, 33], two in 
Amsterdam [27, 34], two in USA [35, 36] and one in Canada [37]. All but one study limited inclusion 
to specific diagnoses or cohorts of patients: “warfarinised” [25, 26]; older age and/or polypharmacy 
[27, 28, 30, 33, 34, 35]; cardiological related conditions [29, 31, 32, 36] and  respiratory disorders 
[37]. One study recruited patients from a general ward of a wide age range, 16-79 years old, and 
excluding only based on presence of psychotic illness or alcohol abuse [19]. 
Study validity  
Six of the studies reported some statistical differences in baseline characteristics between their 
intervention and control groups [25-27, 30, 35]. The majority (n=10) of studies clearly described the 
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patient flow, and where and why losses or drop-out occurred [19, 25, 26, 29-33, 36, 37]. In most of 
these studies, the retention rate was > 80%. However, one study did not include a flow diagram [28], 
but made reference to the previously reported trial [29], and another trial was reported as an 
abstract so lacked much of the required information for quality assessment [34]. Sample size 
calculations were reported in 64% of studies (n=9/14) [25, 26, 28, 30, 31, 33, 35-37], but only half 
achieved their required quota [25, 26, 28, 31]. All studies clearly defined their primary and/or 
secondary outcomes, and stipulated as and when specific resources or funding was utilised in the 
implementation of the interventions. 
Interventions 
Table 1 outlines the key characteristics of the individual interventions. This includes the year the 
study was published, the healthcare professional involved (e.g., hospital pharmacist), and the 
classification of the intervention (e.g., information, coordination, communication). Two of the 
Australian studies reported on interventions delivered by a pharmacist belonging to the Home 
Medicine Review (HMR) programme [25, 26]. This Programme provided governmental remuneration 
for appropriately accredited pharmacists, who are generally based in community pharmacies, to 
carry out home visits to review medication and provide education and counselling. In these studies, 
the pharmacists had to undertake additional training in the area of warfarin therapeutics and patient 
education. In another group of related studies, pharmacists with a postgraduate qualification or 
recent continued professional development in therapeutics also had to receive additional training in 
heart failure, drugs used, exercise, diet, smoking cessation and communication skills [28, 29, 32]. 
Two studies ensured pharmacists received training on the use of the intervention protocol [33,36], 
and two studies involved reimbursement for pharmacists participating in the trial [31,36]. One study 
in USA only considered pharmacists providing services within CommUnity Care health centres, which 
specifically provide services to the medically underserved [30]. The remaining Australian study made 
use of a transition pharmacist (TP) who coordinated the medication communication transfer to 
primary care, community pharmacy and GP [30]. Only four trials reported utilising existing 
pharmacist roles, with no further training or funding deemed necessary [19, 27, 34, 37].  The 
majority of the interventions (n=9) involved the community pharmacist making a home visit [25-30, 
32, 33, 35], one involved telephonic communication [36], one was face-to-face interaction in the 
community pharmacy [31], and three were unclear to the authors as they were not described in 
detail [19, 34, 37]. These different forms of communication and interaction were performed in order 
to carry out a follow-up interview to provide education, counselling, check adherence and 
medication issues, remove inappropriate/excess medications and provide information on laboratory 
monitoring. Both primary and secondary outcomes measured were diverse, often with different 
measuring scales and in the majority of cases showing little agreement amongst studies (Table 2). Of 
the ten studies whose interventions involved increased information sharing between providers; 
improved coordination of care and improved communication, seven showed some statistically 
significantly positive outcomes. 
Outcomes 
Our review has identified some interventions that demonstrate outcomes that are significantly more 
preferable to those receiving standard care (n=5) (two studies reported on the different outcomes of 
the same intervention), others that have negative effects (n=3) (two studies reported on the 
different outcomes of the same intervention) and some that have no impact (n=2). Table 2 provides 
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further details on the outcomes reported for each study and the positive, negative and lack of 
statistically significant results. Only the outcomes that resulted from identification and rectification 
of drug reported problems received unanimous statistically significant positive effects with the 
intervention(s). Of the key primary outcomes, such as hospital readmissions, mortality, patient 
medication adherence and the wider outcomes of quality of life and patient satisfaction, there was 
either no significant difference awarded with the intervention or little agreement between trials. 
The factor of reimbursement or additional pharmacist support (either via a liaison pharmacist or 
specialist training in the intervention) did not contribute to improved trial outcomes across the 
studies. We found no population group characteristic was associated with significantly improved trial 
outcomes. However, six of the nine interventions that incorporated the three recognised 
characteristics of information sharing, coordination of care and communication did demonstrate 
some outcomes classified as statistically significant, which suggests the importance of these 
particular factors in the design and delivery of interventions to improve transfer of care. 
 
Discussion 
Main study findings 
This work has indicated there is a role to be played by community pharmacists in improving the 
transfer of care for post-discharged patients.  However, due to the design and implementation of 
these studies, the full potential of these interventions may not be, as yet, fully realised.  The 
evidence suggests a need for randomised controlled trials that have a more stringent outline for the 
control rather than comparison to uncontrolled ‘usual care’. Caution should be heeded to regulate 
and account for activities that can take place in the control group that have characteristics similar to 
the intervention and can impact on subsequent outcomes reducing potential differences between 
the groups (ref).  Protocol violations also need to be minimised to ensure standardised delivery of 
the intervention and allow for subsequent accurate evaluation of outcomes. Thompson and 
Schoenfeld [38] discussed how the use of usual care in a two-armed randomised controlled trial is 
appropriate for drug and devices and for non-pharmacological interventions that lie well outside of 
usual care practices. Adhering to these principles improves the investigation and deduction of 
findings regarding impact through the minimisation of confounding factors. The observed 
inconsistencies in practice in these particular studies make usual care difficult to understand and 
describe, therefore limiting its value as a comparator arm in the trial. Thompson and Schoenfeld 
suggest the use of a strict protocol and computer-aided decision support to improve both usual care 
and intervention group [38].  
Strengths and weaknesses of the study 
Our search strategy included key databases and was supplemented by reviewing the references of 
relevant studies, review articles and conducting a citation search of identified studies. Where 
insufficient information was included in studies, authors were contacted. Our inclusion criteria were 
wide enough to capture any intervention made by a community pharmacist at the primary-
secondary care interface and did not exclude on the specifics of the populations, the interventions or 
outcomes reported. It became clear from our early literature search that the role of pharmacists, not 
specifically community pharmacists, is one that offers much potential to improve the transfer of 
patient care. Many studies reported on interventions solely performed by clinical pharmacists, 
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hospital-based pharmacists or a liaison pharmacist that was not necessarily based in community, all 
of which were excluded in this review. This offers another perspective to investigate the particular 
characteristics, location and profile of a pharmacist that is a prerequisite of a ‘successful’ 
intervention. Our main focus was to concentrate on evaluating controlled studies only; we recognise 
this as a rigorous method for determining whether a cause-effect relation exists between 
intervention and outcome. However, in our systematic review, it was clear that much research exists 
of a qualitative and uncontrolled nature which could highlight some valuable lessons in the design 
and implementation of the interventions. The Medical Research Council has described that an 
evaluation of a complex intervention, which these transfer of care interventions can generally be 
considered to be, must include the investigation of how the intervention works. A more descriptive 
analysis of the context would facilitate the identification of the key active ingredients of an 
intervention, allowing for a better understanding of the causal mechanisms [39]. Hence, a process 
evaluation should complement an evaluation of effectiveness of any complex intervention. 
Unfortunately, due to the heterogeneous nature of the patient populations tested, the baseline risk 
and opportunity to impact on outcomes may have differed amongst trials, as patients may have 
been in receipt of varying types of care provision from other sources within the healthcare system. 
This was keenly referred to in the intervention evaluations reported by Stafford et al, where 
“warfarinised” patients, even in the control group received a contact visit with a GP eight days after 
discharge that could have shared components of monitoring, counselling, or medicines management 
information similar to that of the pharmacist intervention [25,26]. Also the variation in patient 
groups between studies, including age, comorbidities, etc., may have made them more or less 
vulnerable to poor outcomes, therefore affecting the impact potential of the evaluated intervention. 
Unstandardized delivery of the interventions, violations in protocols across providing pharmacies, 
and between individual pharmacists and even between patients from the same pharmacists, may 
have veiled beneficial effects in certain situations. 
As reported in a previous review [1] that focussed on any interventions made by any primary care 
providers at hospital discharge, we found that the intensity in intervention (number of interactions 
with the community pharmacist) did not appear to correlate directly to the effectiveness of the 
intervention. This reflects upon the complexity of factors to consider in the design and 
implementation of a ‘successful’ intervention. The evaluation of the qualitative and uncontrolled 
studies may shed further light onto the context and the interplay of patient, pharmacist and non-
pharmacist issues and in turn the design of future interventions.  
Findings in comparison with other studies 
This is the only review we are aware of that focusses on interventions involving community 
pharmacists made to improve the continuity of patient care PD from hospital. Unfortunately, before 
now there has been little pooled evidence around community pharmacist-led interventions. The 
findings do agree in essence with related evaluations of interventions in the transfer of patients 
between primary and secondary care.  A recent systematic review of patient handovers from 
secondary to primary care at discharge by Hesselink et al. [1] describes that most interventions 
focussed on the sharing of discharge information, facilitation of continuity of care, and direct and 
timely communication between healthcare providers. The authors also deduced that no singular 
intervention was evidenced to guarantee positive effects on specific outcome measures. There was 
an acknowledgement that their review, in common with this review, evaluates complex 
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interventions, including the number of interactions between components, the un-standardised 
delivery and receipt of interventions, the variability in targeting of the interventions, the number 
and diversity of outcomes and the degree of flexibility or tailoring of intervention components. It 
therefore becomes very problematic to isolate the fundamental role of any player or characteristic 
of that intervention [40]. This remains an issue despite the majority of the studies being classed as 
clear or very clear in their assessment for clarity of reporting against the CONSORT statement.  
Another review, that specifically looked at medication reviews in older patients as an intervention to 
reduce hospital readmissions, reported how variations in the delivery of care and patient selection 
hindered the ability to recommend consistent benefit from such interventions [41]. Okumura et al. 
[42] also concluded that the poor description of the counselling interventions evaluated in their 
review weakened their critique and subsequent evidence to support patient counselling as a robust 
intervention to improve patient outcomes. They advocated that clinical pharmacy services should 
adopt a systematic tool, e.g. DEPICT: Descriptive Elements of Pharmacist Interventions 
Characterisation Tool [40], to allow better understanding of the service and its components to 
ensure reproducibility and standardisation of delivery. Also, if a process evaluation is nested in a trial 
it can be used to assess fidelity and quality of implementation, clarify causal mechanisms and 
identify contextual factors associated with variation in outcomes [39].   
 
Conclusion 
This review provides evidence to support the role of community pharmacists in identifying and 
rectifying medication errors post discharge, as part of interventions aiming to improve the transfer 
of care. However, insufficient data and flawed study design and implementation mean that further 
impact on patient outcomes cannot be deduced. To demonstrate consistent benefit more studies 
are required which are stricter in their intervention and usual care arms. Clear delineation will 
facilitate causal relationships to be better explored. Studies should also include process evaluations 
as standard so that contextual factors can be accounted for. These research modifications will 
improve the evidence base to inform future interventions and potentially describe the facilitative 
accompanying environment required to successfully improve continuity of care. 
Our findings are important at a time when many community pharmacies in the UK are responding to 
the recent RPS guidance to improve transfer of care. Until now MURs and NMS are services accessed 
by discharged patients, despite the lack of empirical robust data to support their potential in 
improving continuity of care. Although medicine related outcomes have here been evidenced, 
community pharmacy has yet to provide convincing verification of the impact on a range of 
economic, clinical and humanistic outcomes. If other interventions, excluding community pharmacy, 
are able to robustly demonstrate such collective effects on the continuity of care, the clinical 
qualities and role of community pharmacy in patient care will not be fully realised and possibly 
ignored. It is important that we recognise how more work needs to be done in this important area.  
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Table 1. Intervention characteristics 
Study, Year 
[Ref] 
Intervention characteristics Key players Classification of intervention 
Information  Coordination  Communication  
Duggan 1998 
[19] 
Patients were given a letter on discharge that documented their prescribed medication and were asked to 
give this to their CP. The CP would compare the discharged medication list to the medications subsequently 
prescribed by the GP and report any discrepancies. 
Hospital 
pharmacy, CP, 
GP 
√ √ √ 
 Stafford 
2011, 2012 
[25, 26] 
Prior to hospital discharge, the HMR referral process was initiated.  At discharge all community-based 
healthcare providers received summary of patient’s inpatient warfarin therapy in addition to usual discharge 
summary. 2-3 home visits by CP, the first within 8-10 days PD. Visits involved medication review, INR 
monitoring and targeted warfarin education, referrals to GP where necessary. 
Hospital 
pharmacy, CP, 
GP 
√ √ √ 
Nazareth 
2001 [33] 
Hospital pharmacist assessed medication, rationalisation of treatment, assessment of patient’s ability to 
manage their medication, provision of drug information and liaison with carers and community professionals. 
Discharge plan was given to patient and CP and GP and any other relevant healthcare professional involved. 
CP made home visit 7-14 days PD to check discrepancies with medication being taken and those prescribed. 
CP assessed patient’s understanding of and adherence to regimen and intervened where appropriate. CPs 
arranged further visits at their own discretion. 
Hospital 
pharmacist, CP, 
GP, other 
healthcare 
professionals 
√ √ √ 
Bellone 2012 
[35] 
A CP visit within 60 days PD that could have included a number of interventions: discontinuation/initiation of 
drug therapy, dosage adjustments, medication counselling, adherence counselling and laboratory 
monitoring. 
CP    
Beachesne 
2007 [37] 
Medication history carried out by clinical pharmacist and communicated information with CP. On discharge 
clinical pharmacist counsels on discharge medication and completes a discharge plan including admission 
diagnosis, comorbidities, allergies/drug intolerances, medications pre-admission, changes made and contact 
details of hospital pharmacist. In intervention group additionally a list of 3 DRPs with proposed actions to 
resolve them were included and CP was phoned and faxed information. 
Hospital 
pharmacy, CP 
√ √ √ 
Hutenberg 
2009 [27] 
Usual care included fax of discharge prescription to CP, also newly prescribed drugs are accompanied with 
personalised letters of information, and patients receive additional oral information. The intervention added 
in a check by CP of drugs pre- and post-hospitalisation and differences were recorded and ay subsequent 
intervention made as a consequence. Other interventions included taking a medication passport, producing a 
daily medication scheme, sending these to patient and GP, synchronising discharge and concomitant 
medication on time, interviewing patient and checking home drug supplies. Interventions were not 
standardised. 
Hospital 
pharmacy, CP, 
GP 
√ √ √ 
Hutenberg 
2012 [34] 
CP performed a medication review at discharge, after 3, 6 and 9 months PD. CP, pharmacy 
technicians and 
not clear who 
else 
   
Holland 2005 
[32] 
Discharge letter sent to CP. CP arranged home visits to assess patient’s ability to self-medicate and drug 
adherence. Educated patient and proxies, removed out of date drugs, reported ADR or interactions to GP, 
and reported need for compliance aid to local pharmacy. One follow-up visit at 6-8 weeks PD to review and 
reinforce original advice.  
Hospital, CP, GP √ √ √ 
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Holland 2007 
[29] 
Pacini 2007 
[28] 
CP made home visit within 2 weeks PD to provide patient medication education and lifestyle advice. Patients 
also completed a sign and symptom monitoring diary card. Recommendations were fed back to GP. One 
follow-up visit at 6-8 weeks PD to review and reinforce original advice.  
CP  √ √ 
Gurjal 2014 
[31] 
CP reviewed patient monthly to assess if medication was being collected and record any DRP. AT 3 and 6 
months PD longer discussions were tailored to medication beliefs informed by researcher. CP funded 
Researcher, CP    
Calvert 2012 
[36] 
At discharge standardised adherence counselling from study pharmacist and medication review. Provided a 
pocket medication card, a list of tips for remembering to take medications and pillbox. Fax of medication, 
and barriers to adherence sent to CP. Study pharmacist called patient 1-2 weeks PD to confirm collection of 
medication. CP verified adherence immediately and 6, 12, 18 and 24 weeks PD. When medication stopped or 
missed or any intervention was sent to study pharmacist and/or GP. CP funded. 
Study 
pharmacist, CP. 
√ √ √ 
Crotty 2004 
[30] 
On hospital discharge to long term facility, physician and CP faxed a medication transfer summary compiled 
by transition pharmacist (TP). TP organised medication review by CP within 10-14 days PD, and a case 
conference involving him/her, the CP, physician and nurse at the facility with 14-28 days PD. 
TP, CP, 
physician, nurse 
√ √ √ 
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Table 2. The types of outcomes and statistical significance of effects by studied interventions. 
 
ⱡ Outcome with statistically significant effect in favour of the intervention. 
ⱡ∏ Outcome with statistically significant effect in a subgroup population in favour of the intervention. 
Study, Year 
[Ref] 
Outcome 
Hospital use Identification 
(no. and type) 
of DRP 
Rectification 
(no. and type) 
of DRP 
Medication 
adherence 
Patient 
knowledge 
Patient 
satisfaction 
Death Quality 
of life 
Quality of 
prescribing 
Clinical 
adverse 
effects 
Condition 
control 
Economic 
evaluation 
Stafford 2011 
[25] 
√   √   √   √ⱡ √  
 Stafford 2012 
[26] 
    √ⱡ        
Nazareth 2001 
[33] 
√   √ √ √ √ √     
Bellone 2012 
[35] 
√ⱡ            
Beachesne 
2007 [37] 
 √ⱡ √ⱡ          
Hutenberg 
2009 [27] 
 √ⱡ √ⱡ   √ⱡ √     √ 
Hutenberg 
2012 [37] 
 √ⱡ           
Holland 2005 
[34] 
√−      
 
√ √     
Holland 2007 
[29] 
√   √  √ √ √     
Pacini 2007 
[28] 
           √ 
Gurjal 2014 
[31] 
   √         
Calvert 2012 
[36] 
   √ⱡ∏         
Crotty 2004 
[30] 
√ⱡ        √ⱡ √ √ⱡ∏  
Total  
 
6 4 2 6 2 4 5 3 1 2 2 2 
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